Tests carried out on collagen peptides suggests they may play a role in reducing the intensity of knee joint pain in healthy adults, potentially delaying the onset of chronic degenerative joint diseases. In a German-Austrian research collaboration, the team found a five gram(g) oral daily dosage of Gelita’s Fortigel bioactive collagen peptides had a “positive effect” on knee joint pain during activity when compared with placebo. “I welcome the new addition to the portfolio of studies,” says Dr Stephan Hausmanns, Gelita’s Vice President for Health & Nutrition. “Fortigel is the most clinically-studied bioactive collagen peptide for 30 years. “Over 20 studies, involving more than 2,500 participants, contributed to develop Fortigel and prove the product’s positive effects to joint health.